| Cat. No. |
Product Name |
Information |
| PC-20093 |
ACT-774312
CRTH2 inhibitor
|
ACT-774312 (ACT774312) is a potent and selective CRTH2 receptor antagonist with IC50 of 3 nM, 150-fold more potent than setipiprant in inhibiting PGD2-induced eosinophil cell shape change. |
| PC-20092 |
Setipiprant
CRTH2 inhibitor
|
Setipiprant (ACT-129968, KYTH-105) is a potent, selective and orally available CRTH2 antagonist with IC50 of 6 nM. |
| PC-20091 |
NVP-QAV680
CRTH2 inhibitor
|
NVP-QAV680 (QAV680) is a potent and selective CRTh2 receptor antagonist with Ki of 36 nM and IC50 of 147 nM in 3H-PGD2 filtration binding assays and cAMP whole cell assays, respectively. |
| PC-49574 |
TG11-77
EP2 antagonist
|
TG11-77 is a potent, selective, brain-permeable and orally available antagonist of the prostaglandin E2 (PGE2) receptor subtype EP2 with KB value of 9.7 nM. |
| PC-49034 |
KMN-159
EP4 agonist
|
KMN-159 is a potent, selective small-molecule full agonist of the prostaglandin E2 type 4 (EP4) receptor with Ki of 0.24 nM (rEP4) and EC50 of 10.6 nM in the BMC ALP assays, with no affinity for EP2 (Ki>10,000 nM). |
| PC-38844 |
OC000459
DP2 (CRTh2) inhibitor
|
OC000459 is a potent, selective, and orally active D prostanoid receptor 2 (DP2, CRTH2) antagonist with Ki of 13/3 nM for human/recombinant DP2, respectively. |
| PC-38519 |
ONO-8130
EP1 antagonist
|
ONO-8130 is a selective, orally bioavailable antagonist of prostaglandin E2 (PGE2) receptor EP1 with Ki value of 1.9 nM, >1,000-fold selectivity for EP1 over other EP receptors. |
| PC-72851 |
TG8-260
EP2 antagonist
|
TG8-260 is a second-generation, potent, selective EP2 antagonist with Schild KB of 13.2 nM. |
| PC-38004 |
HL-43
EP4 antagonist
|
HL-43 (EP4 antagonist HL-43) is a selective prostaglandin E receptor 4 (EP4) antagonist, promotes chondrocyte differentiation/cartilage regeneration and anabolism with low toxicity. |
| PC-36059 |
MF-766
EP4 antagonist
|
MF-766 (MF766) is a highly potent and selective EP(4) antagonist with binding Ki of 0.23 nM, displays no significant affinity (>7000-fold selectivity) against other PG receptors (IC50>1500 nM). |
| PC-36058 |
BGC20-1531
EP4 antagonist
|
BGC20-1531 (PGN-1531, AP 1531) is a potent, selective prostanoid EP receptor EP antagonist, exhibits high affinity at recombinant human EP4 receptors expressed in cell lines (pKB=7.6) and native EP4 receptors in human cerebral and meningeal artery (pKB=7.6-7.8). |
| PC-36057 |
BAY1316957
EP4 antagonist
|
BAY1316957 (BAY 1316957) is a highly potent, selective, orally available human prostaglandin E2 receptor subtype 4 (hEP4-R) antagonist with IC50 of 15.3 nM. |
